Study of Oxycyte in Severe Closed Head Injury

Traumatic Brain Injury Clinical Trial

Official title:

An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00174980
• Other study ID #: OX-CL-II-002
• Status: Completed
• Phase: Phase 2
• First received: September 9, 2005
• Last updated: June 9, 2011
• Start date: September 2005
• Est. completion date: July 2008

Study information

• Verified date: October 2008
• Source: Tenax Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in better brain oxygen consumption, less cell death, and better functional outcome. This study will test the hypothesis that Oxycyte is an effective way to increase brain oxygen levels in severe head injury.

Description:

Decreased brain oxygen in severe brain injuries appears to be implicated in poor functional outcome and death. Animal and clinical studies have shown that increasing brain oxygen in such patients improves functional outcome, and Oxycyte has been shown to be an effective means of delivering oxygen to tissues, including the brain. This study is an eight patient proof of concept study to test the effects of oxygen delivery with Oxycyte in patients with a severe traumatic head injury with a Glasgow Coma Scale (GCS) score of 3 to 9.

Subjects diagnosed with a severe head injury (GCS 3-9) who receive a brain oxygen monitor and microdialysis catheter, will undergo baseline monitoring for 4 hours. In the first 4 subjects the Fi02 on the ventilator will be increased to 50% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 50% for 24 hours.

In the second 4 subjects the Fi02 on the ventilator will be increased to 100% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 100% for 24 hours.

Subjects will be enrolled, treated, and then monitored by LICOX 02 monitor before and after infusion of PFC, and then for at least 48 hours following the discontinuation of Oxycyte.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: July 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• severe closed head injury patients or GCS 3-9 patients who receive brain oxygen monitoring

• ventriculostomy/ICP monitor

• at least one reactive pupil

• no known life threatening disease prior to trauma

• age 18-70 years old

• consent for microdialysis/brain 02 monitoring

• legal family representative present that can give informed consent for perfluorocarbon administration

Exclusion Criteria:

• no motor response

• both pupils fixed and dilated

• no consent available

• allergy to egg proteins

• coagulopathy

• major liver injury

• major pulmonary injury

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Craniocerebral Trauma
• Traumatic Brain Injury
• Wounds and Injuries

Intervention

Drug:
• perfluorocarbon emulsion (Oxycyte) infusion
one time dose of 3mL/kg over 15 minutes

Locations

Country	Name	City	State
United States	Virginia Commonwealth University Medical Center	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Tenax Therapeutics, Inc.	Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Increase in Brain Oxygen Tension levels in severe traumatic head injury patients with GCS score of 3-9
Secondary	Adverse events will be captured throughout drug infusion and 2 weeks post, Severe adverse events will be captured for 6 months. Glascow outcomes score at 3 and 6 months